Navigation Links
Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience

LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Apr 26, 2007 - Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced today the publication* in the April 18, 2007 issue of the Journal of Neuroscience a study by researchers at the University of Colorado and National Jewish Medical and Research Center demonstrating that the Company's first orally available catalytic antioxidant, AEOL 11207, demonstrated neuroprotection in an animal model of Parkinson's disease ("PD"). The study also showed that the compound has favorable blood-brain barrier permeability.

AEOL 11207 was tested for neuroprotection and oral bio-availability in the mouse MPTP model of Parkinson's disease. AEOL 11207 administered orally protected against MPTP-induced dopamine depletion in the striatum as well as dopaminergic neuronal loss, glutathione depletion, lipid peroxidation, and 3-nitrotyrosine formation in the ventral midbrain. Neuroprotection correlated with brain metalloporphyrin concentrations. The researchers concluded that AEOL 11207 demonstrated neuroprotection in the MPTP mouse model and that the data support further investigation of AEOL 11207 as a potential treatment for PD and other neuro-degenerative diseases.

The Potential for AEOL 11207 in Parkinson's and other Neurodegenerative Diseases

A major hurdle to the treatment of chronic neurodegenerative diseases is the development of efficacious and bioavailable therapeutic agents that permeate the blood-brain barrier. Catalytic removal of reactive species is a highly warranted, yet novel approach for the treatment of age related neurodegenerative diseases such as PD. The major therapeutic approach currently used to alleviate the symptoms of PD involves restoration of dopaminergic neurotransmission using levodopa, dopamine agonists, and inhibitors of monoamine metabolism. However, these therapeutic approaches are often associated with serious adverse effects and fail to provide long-
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:4/1/2015)... -- Salix Pharmaceuticals, Ltd. (the " Company " or " ... International, Inc. (NYSE: VRX ) (TSX:VRX), today announced ... Make-Whole Fundamental Changes and Merger Event, Fundamental Change Company ... to Purchase (the " Notice ") to holders of ... Notes "), pursuant to the Indenture, dated as of ...
(Date:4/1/2015)... Trinity Biotech plc (Nasdaq: TRIB ... products for the point-of-care and clinical laboratory markets, ... wholly-owned subsidiary (the "Issuer"), intends to offer, subject ... principal amount of Exchangeable Senior Notes due 2045 ... pursuant to Rule 144A under the Securities Act ...
(Date:4/1/2015)... , April 1, 2015  Pittman Motors ... introduction of PLG24, PLG42K, PLG42S, PLG52, and PLG63 ... Pittman brush and brushless DC motors and complement ... new products add 35 standard motor-gearbox family combinations ... planetary gearboxes deliver high torque loads with excellent ...
Breaking Medicine Technology:Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 2.75% Convertible Senior Notes Due 2015 2Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 2.75% Convertible Senior Notes Due 2015 3Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 2.75% Convertible Senior Notes Due 2015 4Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 2.75% Convertible Senior Notes Due 2015 5Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 2.75% Convertible Senior Notes Due 2015 6Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 2.75% Convertible Senior Notes Due 2015 7Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 2Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 3Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 4Pittman Motors Expands PLG Planetary Gearbox Offering 2
... Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that ... Health Care Conference on Wednesday, March 9, 2011 at 11:00 ... Interested parties may access a live webcast of the presentation ... It is recommended that listeners log on 15 ...
... A new ad campaign warns Mississippi legislators that ... prescription drug benefits and undermine the ability of pharmacy ... Mississippi families and businesses, said the Pharmaceutical Care Management ... put the State Board of Pharmacy (instead of the ...
Cached Medicine Technology:Onyx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2New Ad Campaign: Secret Provision Raises Taxes on Prescription Drug Benefits, Creates 'Conflict of Interest' 2
(Date:4/1/2015)... MD (PRWEB) April 01, 2015 ... free informational seminars in April to discuss the benefits ... for those suffering from periodontal disease. People who ... and suffer from gum disease can now visit Dr. ... to traditional gum surgery. With the LANAP® protocol, which ...
(Date:4/1/2015)... Peoria, Ill. (PRWEB) April 01, 2015 ... the OSF Healthcare System , was welcomed into ... Dedication Ceremony officiated by Msgr. Paul E. Showalter, vicar ... , The Blessing and Dedication culminated a nearly year-long ... the eleventh OSF HealthCare hospital. Speakers for the morning ...
(Date:4/1/2015)... Aging2.0 , the global innovation ... launch of the Aging2.0 Alliance – a ... technology companies. The announcement was made today at the ... Strategies Forum in San Diego, CA. , ... is now open for additional members. “This is a ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Dr. ... and Distinguished Teaching Professor of the Department of Plastic ... other doctors to review reports of blindness resulting from ... surgery . The group published their study, along with ... Reconstructive Surgery journal. , "We began to see increasing ...
(Date:4/1/2015)... 2015 EB Medicine, leading publisher ... Medicine Practice, and Hospital Medicine Practice, is pleased ... to provide the content from its flagship publication, ... application format available on iPhones, iPads and Android ... AgileMD to develop mobile applications for EB Medicine’s ...
Breaking Medicine News(10 mins):Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 3Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 3
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
... a portable, easy-to-use device for near-patient ... APTT, and ACT. It is designed ... medical offices for hematology and cardiology ... and dialysis centers for determination of ...
Tenderlett finger incision devices are designed to fit the contour of the finger. Tenderlett is available in three different incision depths from toddler to adult and color-code for easy identificat...
The Unistik 3 family of single use safety lancets has 4 models for use across all clinical environments....
Medicine Products: